Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothee Olivier

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Translational Oncology|October 23, 2021
Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental armTimothee Olivier, Vinay Prasad
Journal of Cancer Policy|May 26, 2025
Recommendations of perioperative systemic therapies considering age or comorbidities in the National Comprehensive Cancer Network (NCCN) guidelines and quality of cited evidenceSruthi Ranganathan, Myung Sun Kim, Timothee Olivier, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Translational Oncology|October 23, 2021
Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental armTimothee Olivier, Vinay Prasad
Journal of Cancer Policy|May 26, 2025
Recommendations of perioperative systemic therapies considering age or comorbidities in the National Comprehensive Cancer Network (NCCN) guidelines and quality of cited evidenceSruthi Ranganathan, Myung Sun Kim, Timothee Olivier, et al.
Pageof 1